AbbVie (ABBV) Expected to Announce Earnings on Friday

AbbVie (NYSE:ABBV) will likely be announcing its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect the company to announce earnings of $3.60 per share and revenue of $16.7809 billion for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, July 31, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the company posted $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. On average, analysts expect AbbVie to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

AbbVie Trading Up 0.1%

AbbVie stock opened at $263.58 on Thursday. The firm has a market capitalization of $465.69 billion, a price-to-earnings ratio of 129.84, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. The firm’s fifty day moving average price is $237.54 and its two-hundred day moving average price is $223.60. AbbVie has a 1-year low of $187.62 and a 1-year high of $267.47.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 340.89%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent research reports. Barclays raised their price target on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday. Citigroup increased their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Royal Bank Of Canada raised their target price on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Morgan Stanley lifted their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, BMO Capital Markets upped their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $269.29.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Union approved RINVOQ for adults and adolescents aged 12 and older with severe alopecia areata. The decision was supported by Phase 3 data showing statistically significant scalp, eyebrow and eyelash hair regrowth, including complete scalp regrowth for some patients. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo in patients 12 and older who are candidates for systemic therapy. AbbVie described it as the first and only systemic treatment approved in the EU for this condition, creating another potential revenue opportunity for the drug. RINVOQ vitiligo approval
• Positive Sentiment: The approvals reinforce investor expectations that RINVOQ and Skyrizi can continue replacing Humira as AbbVie’s primary growth engines. The two drugs have been highlighted as key drivers ahead of earnings, while AbbVie’s long dividend-raise record supports its appeal to income-focused investors.
• Positive Sentiment: Unusual options activity showed investors purchasing approximately 19,745 call contracts, about 18% above average call volume. This indicates increased bullish positioning, although options activity is not a guarantee of future performance.
• Neutral Sentiment: Erste Group raised its 2027 EPS forecast for AbbVie to $16.40 from $16.27 but slightly lowered its 2026 estimate to $14.05 from $14.08, leaving the near-term earnings outlook mixed.
• Negative Sentiment: After a strong multiyear rally, valuation concerns and the possibility of “sell the news” volatility could limit further gains, particularly if second-quarter results or guidance do not exceed elevated expectations.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently modified their holdings of ABBV. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie in the 4th quarter worth about $31,000. Quarry LP purchased a new position in shares of AbbVie in the 3rd quarter worth about $41,000. Finally, Jessup Wealth Management Inc bought a new position in AbbVie during the fourth quarter valued at about $42,000. 70.23% of the stock is owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.